TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00022126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT03851107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engagement in 6-week community-based activity program
Description: Participants engage in a 6-week community-based activity program of their choice. In order to engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home. Using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward) the youth will choose a community program. The OT will then search for the appropriate program, identify and remove potential environmental barriers for participation in that activity (e.g., accessibility, equipment) and educate program instructors regarding the youth's specific needs. This process, which includes up to 12 hours of working with the OT, will set the stage for enrolment of the youth in a community program for a period of 6 weeks - the actual intervention phase.
Study: NCT01968837

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Cervical cancer screening
Study: NCT03576131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN1029 (HexaBody®-DR5/DR5)
Description: GEN1029 will be administered intravenously. The dose levels will be determined by the starting dose and the escalation steps taken in the trial.
Study: NCT04259879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Food intake restriction
Study: NCT02593084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Higher Intensity Resistance Training
Description: Bi-weekly resistance training for 12 weeks using multi-joint movements involving both upper and lower extremities (e.g squats). Participants will perform 3-5 sets of 3-6 repetitions at Rating of Perceived Exertion 8/10. The intervention will be administered by a Physical Therapist or trained fitness professional.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lower Intensity Resistance Training
Description: Bi-weekly resistance training for 12 weeks using single-joint movements involving both upper and lower extremities (e.g leg extension). Participants will perform 3-5 sets of 8-10 repetitions at Rating of Perceived Exertion 5/10. The intervention will be administered by a Physical Therapist or trained fitness professional.
Study: NCT02729025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered subcutaneously once a month using an autoinjector/pen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously once a month using an autoinjector/pen.
Study: NCT01747239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: 25 mg/m2 IV every three weeks
Study: NCT01046721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: single dose of 5 microg Exenatide. Subcutaneous administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: subcutaneous administration of 0.9% saline solution (0.02 ml)
Study: NCT04430101

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Minimally invasive stabilization of Lisfranc injuries
Description: Patients with positive weightbearing radiographs will be operated by minimally invasive stabilization (eg, isolated homerun screw)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Patients with negative weightbearing radiographs will be treated conservatively

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Patients with negative weightbearing radiographs will be treated conservatively
Study: NCT02364219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prewarming
Description: Patients are treated according to standard operating procedures plus prewarming period of at least 30 minutes during induction of combined general and epidural anesthesia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prewarming
Description: Patients are treated according to standard operating procedures plus prewarming period of at least 30 minutes during induction of combined general and epidural anesthesia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microdialysis
Description: 71 High Cut-Off Brain MD Catheter Membrane cut-off: 100 kDa Membrane length 30 mm Shaft length: 60 mm Dialysis AB, Stockholm, Sweden

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microdialysis
Description: 71 High Cut-Off Brain MD Catheter Membrane cut-off: 100 kDa Membrane length 30 mm Shaft length: 60 mm Dialysis AB, Stockholm, Sweden
Study: NCT03940027

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided celiac plexus neurolysis
Description: EUS-guided celiac plexus neurolysis (EUE-CPN) is an endoscopic ultrasound-guided injection of local anesthetics and neurodegenerative agents into the abdominal ganglion area through the gastric wall, so as to achieve irreversible damage of the abdominal nerve and interrupt the pain pathway of pancreatic cancer.EUS-CPN has the advantages of less trauma, higher technical success rate and lower risk of complications compared with traditional ct-guided CPN in vitro puncture.The data showed that eus-cpn was effective in the treatment of pancreatic cancer related persistent abdominal pain up to about 70%, significantly reducing the dosage of analgesics and improving the quality of life of patients with advanced pancreatic cancer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided celiac plexus neurolysis
Description: EUS-guided celiac plexus neurolysis (EUE-CPN) is an endoscopic ultrasound-guided injection of local anesthetics and neurodegenerative agents into the abdominal ganglion area through the gastric wall, so as to achieve irreversible damage of the abdominal nerve and interrupt the pain pathway of pancreatic cancer.EUS-CPN has the advantages of less trauma, higher technical success rate and lower risk of complications compared with traditional ct-guided CPN in vitro puncture.The data showed that eus-cpn was effective in the treatment of pancreatic cancer related persistent abdominal pain up to about 70%, significantly reducing the dosage of analgesics and improving the quality of life of patients with advanced pancreatic cancer.
Study: NCT04529499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVIGAN
Description: Patients will be randomized to the favipiravir + supportive care group in a 1:1 ratio

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Patients will be randomized to the placebo + supportive care group in a 1:1 ratio
Study: NCT01154400

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Casein protein hydrolysates
Description: 15 g casein protein hydrolysates + 15 g maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein hydrolysates
Description: 15 g whey protein isolate + 15 g maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Casein protein hydrolysates + LEU
Description: 15 g casein protein hydrolysate + 2.1 g LEU (40% of EAA content) + 15 g maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein hydrolysates + LEU
Description: 15 g whey protein isolate + 1.5 g LEU (40% of EAA content) + 15 g maltodextrion
Study: NCT00861731

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: simvasatin therapy alone at the dose of 40 mg/day
Study: NCT01514981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 761
Description: Single dose of AMG 761 on study day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo on study day 1.
Study: NCT03101631

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA)
Description: CGA includes a set of evaluations to determine therapeutic decision based on mortality risk, toxicity risk and frailty group. Evaluations includes:~* Nutritional Assessment: Mini Nutritional Assessment (MNA)~* Functional Assessment: Get up and Go, Activities of Daily Living (ADL), Instrumental Activities of Daily Living (IADL), Karnofsky Scale, Walking one Block, Number of Falls in last 6 months and Hearing Loss.~* Cognitive Assessment: Mini-Mental State Examination (MMSE-30)~* Psychological status: Geriatric Depression Scale (GDS)~* Social Support: Medical Outcomes Study Social Support Survey (MOS-SSS)~* Comorbidity and Severity of Comorbidities: Charlson Comorbidity Index and Adult Comorbidity Evaluation (ACE-27)~* Age~* Haemoglobin~* CrCl~* Presence of geriatric syndromes
Study: NCT04593485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab for injection
Description: Carrelizumab will be administered at a fixed dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab for injection
Description: Carrelizumab will be administered at a fixed dose
Study: NCT04209452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehearsal strategy
Description: Teaching children to cumulatively rehearse numbers as they are being said.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement
Description: Providing reinforcement for correct recall after a delay.
Study: NCT00861731

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: EZE/simvastatin
Description: EZE/simvastatin combined therapy at the dose of 10/20 mg/day

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: EZE/simvastatin
Description: EZE/simvastatin combined therapy at the dose of 10/40 mg/day
Study: NCT04488731

Intervention type: BEHAVIORAL
Intervention: Normal BMI and heavy coffee consumption
Description: Normal BMI and heavy coffee consumption

Intervention type: BEHAVIORAL
Intervention: overweight and moderate coffee consumption
Description: overweight and moderate coffee consumption
Study: NCT04209452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehearsal strategy and reinforcement
Description: Teaching children to cumulatively rehearse numbers as they are being said, AND providing reinforcement for correct recall after a delay.
Study: NCT03751033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BSS
Description: Intraoperative aberrometry measurements for BSS will be performed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiscoVisc
Description: Intraoperative aberrometry measurements for DiscoVisc will be performed.
Study: NCT04025060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commercially-available caffeine-free soda
Description: Subjects are asked to consume caffeine-free soda daily for two weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Carbonated water
Description: Subjects are asked to consume unsweetened, carbonated water daily for two weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular soda
Description: Subjects are asked to consume regular soda daily for two weeks
Study: NCT04468022

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Toric Trifocal IOL
Description: Interventions are performed using a standard technique of sutureless phacoemulsification. In all cases, topical anesthesia was administered and pharmacologic mydriasis was induced using a combination of tropicamide and phenylephrine (10.0%). A mean clear corneal microincision of 2.2 mm was made with a knife according to position of the preop highest K value of the patient. A paracentesis was made 60 degree to 80 degree, clockwise from the main incision, and the anterior chamber was filled with an ophthalmic viscoelastic (OVD) after phacoemulsification/lensectomy and removal of clear lens. The IOL was subsequently implanted through the main incision using the BLUEMIXS 180 injector (Carl Zeiss meditec, Jena, Germany) for trifocal IOL , VISCOJECTTM BIO injector for toric trifocal IOL and then the OVD was removed. Postoperative pharmacologic treatment is performed with the combination of antibiotic and steroidal anti-inflammatory drops

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Toric Trifocal IOL
Description: Interventions are performed using a standard technique of sutureless phacoemulsification. In all cases, topical anesthesia was administered and pharmacologic mydriasis was induced using a combination of tropicamide and phenylephrine (10.0%). A mean clear corneal microincision of 2.2 mm was made with a knife according to position of the preop highest K value of the patient. A paracentesis was made 60 degree to 80 degree, clockwise from the main incision, and the anterior chamber was filled with an ophthalmic viscoelastic (OVD) after phacoemulsification/lensectomy and removal of clear lens. The IOL was subsequently implanted through the main incision using the BLUEMIXS 180 injector (Carl Zeiss meditec, Jena, Germany) for trifocal IOL , VISCOJECTTM BIO injector for toric trifocal IOL and then the OVD was removed. Postoperative pharmacologic treatment is performed with the combination of antibiotic and steroidal anti-inflammatory drops
Study: NCT04488731

Intervention type: BEHAVIORAL
Intervention: overweight and heavy coffee consumption
Description: overweight and heavy coffee consumption
Study: NCT02647008

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: Transcutaneous electrical nerve stimulation (TENS) is a nonpharmacological intervention that activates a complex neuronal network to reduce pain by activating descending inhibitory systems in the central nervous system to reduce hyperalgesia.These small battery powered devices deliver alternating current via cutaneous electrodes positioned near the painful area.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENS
Description: Transcutaneous electrical nerve stimulation (TENS) is a nonpharmacological intervention that activates a complex neuronal network to reduce pain by activating descending inhibitory systems in the central nervous system to reduce hyperalgesia.These small battery powered devices deliver alternating current via cutaneous electrodes positioned near the painful area.
Study: NCT02685228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: decitabine 5mg/m2,d1-d5;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine 1.0g/m2, d8,d15,d22

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: gemcitabine 1.0g/m2, d8,d15,d22
Study: NCT02261272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for insomnia SHUTi
Description: SHUTi
Study: NCT03422081

Intervention type: DIAGNOSTIC_TEST
Intervention: arterial doppler ultrasound
Description: doppler ultrasound

Intervention type: DIAGNOSTIC_TEST
Intervention: arterial doppler ultrasound
Description: doppler ultrasound

Intervention type: DIAGNOSTIC_TEST
Intervention: arterial doppler ultrasound
Description: doppler ultrasound
Study: NCT01472315

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medroxyprogesterone acetate
Description: MPA hormone therapy 30mg two hours before bedtime and 30mg right before going to bed every night for two weeks period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills were taken in same way as active comparator
Study: NCT02111382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CV4 Cranial (4th ventricle technique) Osteopathic Manipulative
Description: The participant will be in supine position during the whole procedure. The practitioner sits behind the participant's head, contacts participant's lateral protuberances of the squama occipitalis (medially to the occipitomastoid suture) with the thenar eminence of both hands.~When the practitioner feels the PRM (a pulsating rhythm caused by liquor production and reabsorption), the flexion phase will be resisted and the extension phase exaggerated. The compressive force is held until the PRM stops (event known as 'Still point'). The compression will be held until the practitioner feels PRM gradual return; the compression will be slowly diminished, and then, the practitioner remove the hands from the occipital bone, laying the participant's head on the table.~The CV4 technique will be performed by an osteopath D.O. - member of the Brazilian Register of Osteopaths.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: CV4 (4th ventricle technique) manual therapy sham technique
Description: The participant will be in supine position and the practitioner will be seated behind the participant's head. The practitioner places the fingers (2nd to 5th) under the occipital bone, touching only the squama occipitalis. The practitioner will hold this position for 5 minutes, and after this period the participant's head will be placed on the table.~The CV4 sham will be performed by a registered physiotherapist.
Study: NCT04390074

Intervention type: OTHER
Intervention: COVID-19 and Intensive Care
Description: No intervention, observational.
Study: NCT03154931

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CBT-SG
Description: To support the group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CFT-G
Description: Teach compassionate skills.
Study: NCT02770053

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Foraminal enlargement
Description: After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Foraminal enlargement
Description: After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.
Study: NCT04303117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NHS-IL12
Description: An initial dose of 16.8 mcg/kg administered subcutaneously every 4 weeks and at an MTD dose with M7824 on day 1 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NHS-IL12
Description: An initial dose of 16.8 mcg/kg administered subcutaneously every 4 weeks and at an MTD dose with M7824 on day 1 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NHS-IL12
Description: An initial dose of 16.8 mcg/kg administered subcutaneously every 4 weeks and at an MTD dose with M7824 on day 1 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: 1200 mg administered IV every two weeks while on NHS-IL12.
Study: NCT01206946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone
Description: A single course of betamethasone (two doses of 12 mg/dose given at 24 hourly intervals)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Two doses of 2ml of normal saline given at 24 hourly intervals
Study: NCT00254488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium (LI)
Description: The starting LI dose will be 150 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma LI level ranges between 0.40 and 0.99 mEq/L (target 0.80 to 0.99 mEq/L).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex (DV)
Description: Dosage of DV will be 250 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma DV level ranges between 40 and 99 mcg/mL (target 80 to 99 mcg/ml).
Study: NCT04310735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Verbal smoking expectancy manipulation
Description: Instructions regarding whether or not participants will have an opportunity to smoke during the experimental session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Verbal smoking expectancy manipulation
Description: Instructions regarding whether or not participants will have an opportunity to smoke during the experimental session.
Study: NCT04398888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Banxie Xiexin Decoction (BXD)
Description: A modified Banxie Xiexin Decoction based on Chinese medicine syndrome differentiation.
Study: NCT02754505

Intervention type: OTHER
Group type: OTHER
Intervention: Early rehabilitation
Description: The early rehabilitation program consisted of a coordinated exercise therapy and neuromuscular electrical stimulation, for two hours and five days a week until discharge from the acute hospital. Exercise therapy included strength training (three days/week, one to three sets of 12-15 repetitions, 8-10 exercises involving the major muscle groups: thighs, calves, buttocks, trunk, shoulder girdle), aerobic exercise (large muscle activities five days/week, 10-30 min/session, 50-80% maximal heart rate) and active breathing techniques. For neuromuscular electrical stimulation we applied Compex-P© devices producing biphasic symmetric impulses with a frequency of 50 Hz and a pulse width of 0.35 ms (stimulus regime: 8 s on/24 s off) five days/week, 30 min/session involving the anterior thighs and buttocks.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: exercise therapy, respiratory therapy, neuromuscular electrical stimulation (as described above).
Study: NCT06537635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cubii seated compact elliptical trainer
Description: The Cubii® Pro is an under-desk seated elliptical trainer. This device provides 8 levels of resistance and documents the total number of strides, distance covered in miles, and calories expended during an activity session.
Study: NCT01702766

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium animalis subsp. lactis
Study: NCT00981864

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent Boost RT
Description: Patient will receive radiation to the tumour bed concurrently with whole breast radiation instead of receiving this treatment sequentially, that is, whole breast RT first then followed by RT directly to the tumour bed.
Study: NCT02261272

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: passive patient education/sleep hygiene